NCT03794349 2026-02-18
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
Children's Oncology Group
Phase 2 Active not recruiting
Clinical Trials
14 trialsNCT06528496 2026-02-10
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06450041 2025-11-04
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
New Approaches to Neuroblastoma Therapy Consortium
Phase 2 Recruiting
NCT06013618 2025-06-17
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
Sun Yat-sen University
Phase 2 Recruiting
NCT03709680 2025-01-14
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Pfizer
Phase 2 Active not recruiting
NCT02308527 2024-05-14
BEACON
University of Birmingham
Phase 2 Active not recruiting
NCT01767194 2022-10-24
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01467986 2020-10-06
RIST-rNB-2011
University of Regensburg
Phase 2 Completed
NCT01114555 2019-11-21
Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00003273 2015-12-03
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
NYU Langone Health
Phase 2 Withdrawn
NCT00098865 2014-10-07
Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00311584 2014-09-30
Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma
Children's Oncology Group
Phase 2 Completed
NCT00276679 2013-09-17
Temozolomide in Treating Young Patients With High-Risk Relapsed or Refractory Neuroblastoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005955 2013-06-20
Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors
Duke University
Phase 2 Completed